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Abstract
Background: Sepsis is an important cause of neonatal death and perinatal brain damage,
particularly in preterm infants. While effective antibiotic treatment is essential treatment for sepsis,
resistance to antibiotics is increasing. Adjuvant therapies, such as intravenous immunoglobulin,
therefore offer an important additional strategy. Three Cochrane systematic reviews of
randomised controlled trials in nearly 6,000 patients suggest that non-specific, polyclonal
intravenous immunoglobulin is safe and reduces sepsis by about 15% when used as prophylaxis but
does not reduce mortality in this situation. When intravenous immunoglobulin is used in the acute
treatment of neonatal sepsis, however, there is a suggestion that it may reduce mortality by 45%.
However, the existing trials of treatment were small and lacked long-term follow-up data.
This study will assess reliably whether treatment of neonatal sepsis with intravenous
immunoglobulin reduces mortality and adverse neuro-developmental outcome.
Methods and design: A randomised, placebo controlled, double blind trial. Babies with suspected
or proven neonatal sepsis will be randomised to receive intravenous immunoglobulin therapy or
placebo.
Eligibility criteria
Babies must be receiving antibiotics and have proven or suspected serious infection AND have at
least one of the following: birthweight less than 1500 g OR evidence of infection in blood culture,
cerebrospinal fluid or usually sterile body fluid OR be receiving respiratory support via an
endotracheal tube AND there is substantial uncertainty that intravenous immunoglobulin is
indicated.
Exclusion criteria
Babies are excluded if intravenous immunoglobulin has already been given OR intravenous
immunoglobulin is thought to be needed OR contra-indicated.
Trial treatment
Babies will be given either 10 ml/kg of intravenous immunoglobulin or identical placebo solution
over 4–6 hours, repeated 48 hours later.
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Mortality or major disability at two years, corrected for gestational age.
Data collection
Data will be collected at discharge from hospital and at 2 years of age (corrected for gestation)
using a parental questionnaire and a health status questionnaire completed during a face-to-face
follow-up appointment with the child's paediatrician.
Trial registration: Current Controlled Trials ISCRTN94984750.
Background
This protocol is for a large, simple-in-design, double
blind, placebo controlled, pragmatic, multicentre ran-
domised trial.
Hypothesis to be tested
That, in infants receiving antibiotics for clinical sepsis, the
addition of non-specific, polyclonal intravenous immu-
noglobulin IgG (IVIG) therapy reduces mortality and
major morbidity compared with antibiotics alone.
Background
Neonatal sepsis is a major cause of mortality and morbid-
ity and has been implicated in the causation of perinatal
brain damage and cerebral palsy, both in term and pre-
term infants [1,2]. Although antibiotics are the mainstay
of therapy, increasing numbers of bacteria are resistant to
them [3,4]. Effective adjunctive strategies are therefore
needed.
Incidence, potential impact on mortality and problems in 
diagnosis
In a prospective study in seven Australian neonatal inten-
sive care units (NICUs), Isaacs and colleagues reported an
annual incidence of sepsis of 6.6 per 1000 live births, of
which 75% were late onset (more than 48 hours after
birth). Overall hospital mortality for sepsis was 10% [5].
In a cohort of 54 UK neonatal units in 1998, 204 (5%) of
3,963 consecutive admissions to neonatal units had a pos-
itive blood culture [6]. Of these, 16 (8%) died. Of 3,759
(95%) babies with negative blood cultures, 95 babies died
(2.5%). For very low birthweight (VLBW) infants with
positive blood cultures, mortality was 14%. In a North
American cohort, mortality in VLBW infants with septi-
caemia was 21% [7]. However, these figures may underes-
timate the true incidence of neonatal sepsis. Blood
cultures may often be negative if less than 1 ml of blood
is sampled [8]. Furthermore, while sepsis was the primary
cause of death in most infants under 1000 g at autopsy, it
was clinically undiagnosed in 61% of cases [9]. Sepsis-
specific mortality rates should therefore be interpreted
with caution, as the diagnosis may often be inaccurate.
More reliable evidence would be provided by randomised
comparisons of the effects of specific interventions on
mortality from all causes.
Potential impact of sepsis on the perinatal brain
Recent evidence suggests that sepsis is also important in
the pathogenesis of neuro-developmental impairment of
perinatal origin. In a case-control study of 424 births,
Grether and Nelson found an association between mater-
nal infection in labour and cerebral palsy in infants with
birthweight of at least 2500 g (OR 9.3, 95% CI 3.7, 23.0).
In another case-control study of 96 term infants, levels of
cytokines in neonatal blood spots were consistently
higher in children diagnosed with cerebral palsy at 3 years
of age than in controls, suggesting that an inflammatory
response may be important in the aetiology of cerebral
impairment [10]. In preterm infants, sepsis is also associ-
ated with subsequent adverse neuro-developmental out-
come [2]. Dammann and Leviton have suggested that
infection remote from the preterm brain may predispose
to cerebral white matter damage with disruption of oli-
godendroglial myelination and disordered migration of
precursors [11]. The damage could result partly from
inadequate endogenous protection from developmentally
regulated factors such as oligotrophins [12]. As antenatal
and postnatal sepsis may predispose to neuro-develop-
mental impairment and disability in term and preterm
infants, these are essential measures of outcome.
Possible adjunctive treatments
Immunoglobulin
Newborn infants, particularly those who are very low
birthweight or preterm, are deficient in IgG, which binds
to cell surface receptors, provides opsonic activity, acti-
vates fixation of complement, promotes antibody
dependent cytotoxicity, improves neutrophil chemilumi-
nescence and phagocytosis and can improve neutropenia
by enhancing the release of stored neutrophils [13-16].
Intravenous immunoglobulin (IVIG) is therefore a theo-
retically attractive strategy, with multiple mechanisms of
action. Its potential clinical relevance is confirmed by
recent evidence from randomised controlled trials (see
below).Page 2 of 13
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In animal models of sepsis, pentoxifylline, a methylxan-
thine deriviative, inhibits production of Tumor Necrosis
Factor (TNF), preserves micro-vascular blood flow, pre-
vents circulatory failure and intestinal vaso-constriction
and improves survival [17,18]. It is well tolerated and
decreases TNF production in adults and preterm infants
with sepsis [19-21]. Two randomised controlled trials
(RCTs) of pentoxifylline recruited 140 preterm infants
with clinical sepsis [21,22]. Among the 107 with positive
blood cultures, pentoxifylline was associated with an 86%
reduction in risk of mortality (RR 0.14, 95% CI 0.03,
0.76). Outcomes for the 33 infants not included in the
analyses are not available. Pentoxifylline may be a prom-
ising therapy in neonatal sepsis.
Cytokines
Other adjunctive strategies for prophylaxis or treatment of
neonatal sepsis are also attractive, such as use of the
recombinant cytokines Granulocyte Colony Stimulating
Factor (G-CSF) or Granulocyte-Macrophage Colony Stim-
ulating Factor (GM-CSF) to prevent neutropenia [23].
However, no systematic reviews of RCTs of these agents
are yet available. In four RCTs of G-CSF therapy which
recruited 125 infants with neonatal sepsis, there was a
trend to reduced mortality which was not statistically sig-
nificant (OR 0.6, 95% CI 0.2,1.8) [24-27].
Two recent RCTs of GM-CSF prophylaxis in a total of 339
high risk infants showed no reduction in sepsis or mortal-
ity [28,29]. However, these findings do not rule out a
moderate benefit [30].
Blood products other than immunoglobulin
White cell (granulocyte) transfusions are also a logical
approach. Although preliminary clinical evidence is
encouraging, there are potential risks from transmission
of infection (e.g. HIV or hepatitis) or from graft-versus-
host disease, and the technology is not widely available
[31]. Exchange transfusion with fresh whole adult blood
appeared effective in one RCT of 22 septicaemic infants,
but may also transmit infection [32]. In another RCT, in
776 infants of less than 32 weeks' gestation, there was no
evidence that prophylactic fresh frozen plasma reduced
the risks of mortality from all causes or of disability in sur-
vivors at 2 years [33].
Overall, therefore, the evidence suggests that IVIG therapy
is one of the most promising strategies in neonatal sepsis
and should be assessed in a definitive RCT.
Non-specific versus specific immunoglobulin
This trial will use non-specific, polyclonal IVIG (normal
human IgG immunoglobulin) produced from plasma
from non-UK donors. It was decided that specific IVIG
would not be used and that there was no necessity to char-
acterise the specific antibacterial profile of the non-spe-
cific IVIG for the following reasons:
1) Previous RCTs of non-specific, polyclonal IVIG in
neonates and adults did not characterise any specific
aspects of antibacterial function in the products used.
There is therefore no reference laboratory data against
which to judge the possible antibacterial efficacy of poly-
clonal IVIG.
2) As the mechanism of action of IVIG is likely to be mul-
tifactorial, the precise aspects of antibacterial function
which should be assessed are speculative.
3) Despite the production of monoclonal antibodies with
demonstrable in vitro and in vivo antibacterial function in
laboratory studies, they have not been associated with
reductions in mortality in RCTs. There is therefore no evi-
dence that laboratory studies which attempt to character-
ise specific aspects of antibacterial function in IVIG
products would be more predictive of clinical efficacy
than the existing clinical evidence from RCTs in support of
non-specific, polyclonal IVIG therapy.
Results of previous randomised controlled trials
A Cochrane systematic review of the prophylactic use of
non-specific IVIG in 15 RCTs with a total of 5,054 preterm
or low birthweight infants has demonstrated that prophy-
lactic, non-specific IVIG reduced sepsis (RR 0.85, 95% CI
0.74, 0.98) and was safe, with no major adverse effects,
but did not demonstrate a definite reduction in mortality
(RR 0.89, 95% CI 0.75, 1.05) [34].
A Cochrane systematic review of reports of RCTs of IVIG
therapy for proven or suspected neonatal sepsis identified
nine studies that reported outcomes for 318 infants with
suspected infection and 262 infants with proven infection
[15,35-43]. IVIG therapy appeared to be safe and was
associated with approximately 40% reduction in the risk
of mortality for both suspected and proven infection
(Tables 1 and 2). However, the confidence intervals were
wide and the studies included in the analyses were small
and not of high methodological quality. Problems identi-
fied by the reviewers were lack of allocation concealment,
lack of blinding of outcome assessment and high levels of
post-randomisation exclusions in some of the trials.
The reviewers concluded that: "The reduced mortality follow-
ing treatment with IVIG for subsequently proven infection, the
imprecise estimate of the effect size (number needed to treat 11,
95% CI 5.6, 100) and the borderline statistical significance for
the outcome of mortality in neonates with suspected infection
justify further research. Researchers should be encouraged toPage 3 of 13
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ness of IVIG" [35].
Using slightly different selection criteria and methods for
analysis, Jenson and Pollock have published a systematic
review of three RCTs of IVIG in neonatal sepsis in which
55 infants received IVIG and 55 received placebo or no
intervention [44]. The odds ratio for mortality in treated
versus control infants was 0.173 (95% CI 0.03, 0.75).
These authors reached a conclusion which many would
consider premature, namely that "IVIG should be considered
as part of the routine therapy of neonatal sepsis". However, it
remains true that, among all the interventions currently
reviewed in the Cochrane Library, IVIG therapy in neona-
tal sepsis is associated with one of the largest reductions in
the odds of death. A further RCT of IVIG in neonatal sepsis
in Brazilian neonatal units is being conducted. One of the
applicants (K Haque) is an investigator of this trial. Its
results will be incorporated into the current meta-analysis
as soon as they are available.
Another Cochrane systematic review and meta-analysis of
intravenous immunoglobulin used for treating sepsis and
septic-shock in all patients (adults, children and
neonates) suggested a beneficial effect of non-specific
IVIG on all cause mortality (RR 0.64, 95% CI 0.51, 0.80)
(Table 3) [45].
A sensitivity analysis was also conducted, including only
seven trials of good and fair quality. This also suggested a
decreased risk of mortality (RR 0.55, 95% CI 0.40, 0.79).
The same Cochrane review also explored the effect of
monoclonal antibodies; the relative risks for both anti-
endotoxins and anti-cytokines were similar and were of
borderline statistical significance (anti-endotoxins RR
0.93, 95% CI 0.85, 1.02; anti-cytokines RR 0.92, 95% CI
0.86, 0.99). The authors concluded that although there
was evidence that non-specific IVIG appears to be benefi-
cial "large, multi-centre studies are needed to confirm the effec-
tiveness of polyclonal IVIGs in reducing mortality in patients
with sepsis. These are particularly indicated for neonatal sepsis,
where evidence for benefit is still conflicting".
Safety: No evidence of transmission of blood borne viruses 
or prion disease
The risk of transmissible infection by blood products
remains a potent source of anxiety for many clinicians and
patients. However, IVIG produced to modern standards of
quality control is one of the safest blood products availa-
Table 1: Mortality in trials of IVIG for suspected infection in neonates
Study Exptl n/N Ctrl n/N Relative Risk (95% CI Fixed) Weight
Christensen 1991 0/11 0/11 not estimable 0
Erdem 1993 6/20 9/24 0.80 [0.34, 1.86] 22.0%
Haque 1988 1/30 6/30 0.17 [0.02, 1.30] 16.1%
Samatha 1997 5/30 8/30 0.62 [0.23, 1.69] 21.5%
Shenoi 1999 7/25 7/25 1.00 [0.41, 2.43] 18.8%
Sidiropoulos 1981 4/41 8/41 0.50 [0.16, 1.53] 21.5%
Total 23/157 38/161 0.63 [0.40, 1.00] 100%
Review: IVIG in neonatal infection
Comparison: IVIG vs placebo or no intervention for suspected infection
Outcome: Mortality from any cause
Table 2: Mortality in trials of IVIG for proven infection in neonates
Study Exptl n/N Ctrl n/N Relative Risk (95% CI Fixed) Weight
Chen 1996 2/28 1/28 2.00 [0.19, 20.82] 3.8%
Erdem 1993 5/15 7/16 0.76 [0.31, 1.89] 25.4%
Haque 1988 1/21 4/23 0.27 [0.03, 2.26] 14.3%
Mancilla-Ramirez 1992 2/19 2/18 0.95 [0.15, 6.03] 7.7%
Samatha 1997 0/12 4/16 0.15 [0.01, 2.46] 14.6%
Sidiropoulos 1981 2/20 4/15 0.38 [0.08, 1.78] 17.2%
Weisman 1992 2/14 5/17 0.49 [0.11, 2.13] 17.0%
Total 14/129 27/133 0.55 [0.31, 0.98] 100%
Review: IVIG in neonatal infection
Comparison: IVIG vs placebo or no intervention for proven infection
Outcome: Mortality from any causePage 4 of 13
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or prions by the IVIG to be used in this study.
Methods of production including ethanol fractionation,
and the use of the pH4/pepsin virus inactivation proce-
dure, in addition to the use of plasma originating from
non-UK donors have reduced the risk of transmission of
infection to an absolute minimum [46,47].
In particular, for prion disease, leucocytes represent the
main source of infectivity in Creutzfeld-Jacob disease.
Owing to the physico-chemical characteristics of the
abnormal prion protein, the process of partitioning and
filtration during fractionation further reduces the risk of
transmission in IVIG [48]. This theoretical risk must be
considered in the context of the significantly increased
risk of mortality and morbidity in infants eligible for the
study.
As a further safeguard, fractionation pools of IVIG are
tested with PCR (polymerase chain reaction) for known
blood borne viruses.
Safety: No evidence of haemolysis related to T activation 
of red cells
Bacteria such as Clostridia can strip neuraminic acid resi-
dues from the red cell membrane, exposing the T antigen
(T activation). Adult plasma contains anti-T antibodies, so
transfusing newborn infants whose red cells are T acti-
vated with whole blood, unwashed red cells or unselected
plasma may lead to polyagglutination and haemolysis
[49]. However, anti-T antibodies are predominantly IgM
immunoglobulins a fraction which is removed from the
IVIG used in this study [50]. T activation is not a contra-
indication to its use in neonatal sepsis.
Although neonatal haemolysis has been noted in associa-
tion with IVIG, it was not clinically significant [51]. The
UK Committee on Safety of Medicines has received no
reports of neonatal haemolysis or other adverse reactions
in association with IVIG over a 30 year period until the
present (personal communication, September 1999).
Current practice
IVIG is not currently widely used for prophylaxis or treat-
ment of neonatal sepsis in UK NICUs. In 1997, a postal
survey of all paediatricians who were members of the Brit-
ish Association of Perinatal Medicine was undertaken into
practice in the investigation and treatment of neonatal
sepsis [52]. Of the 181 (66%) who responded, only 13
(7%) used IVIG routinely as adjuvant therapy alongside
antibiotics.
Summary
There is good preliminary evidence that IVIG therapy may
reduce mortality in severe neonatal sepsis. However, there
is no information on longer term quality of survival, the
number of babies included in the existing systematic
reviews is small and the effect size seems larger than
would be anticipated. As a consequence a reliable multi-
centre trial is needed to provide definitive evidence that
IVIG therapy for severe neonatal sepsis is or is not of ben-
efit, with mortality or major morbidity as the outcome.
IVIG is not yet widely used as routine therapy. There
Table 3: Mortality in trials of IVIG for proven sepsis & septic shock in adults and children
Study Exptl n/N Ctrl n/N Relative Risk (95% CI Fixed) Weight
Standard IVIG vs placebo or no intervention, ACM
Chen 1996 2/28 1/28 2.00 [0.19, 20.82] 0.9%
De Simone 1988 7/12 9/12 0.78 [0.44, 1.39] 8.5%
Dominioni 1991 11/29 22/33 0.57 [0.34, 0.96] 19.3%
Grundmann 1988 15/24 19/22 0.72 [0.51, 1.03] 18.6%
Just 1986 6/13 9/16 0.82 [0.40, 1.70] 7.6%
Shenoi 1999 7/25 7/25 1.00 [0.41, 2.43] 6.6%
Weisman 1992 2/14 5/17 0.49 [0.11, 2.13] 4.2%
Subtotal 50/145 72/153 0.73 [0.57, 0.93] 65.8%
IgM-enriched IVIG vs placebo or no intervention, ACM
Erdem 1993 6/20 9/24 0.80 [0.34, 1.86] 7.7%
Haque 1988 1/30 6/30 0.17 [0.02, 1.30] 5.6%
Schedel 1991 2/27 9/28 0.23 [0.05, 0.97] 8.3%
Wesoly 1990 8/18 13/17 0.58 [0.33, 1.04] 12.6%
Subtotal 17/95 37/99 0.48 [0.30, 0.76] 34.2%
Total 67/240 109/252 0.64 [0.51, 0.80] 100%
Review: Intravenous immunoglobulin for treating sepsis and septic shock
Comparison: Polyclonal IVIG vs placebo or no intervention
Outcome: All-cause mortality (ACM)Page 5 of 13
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such a trial before an intervention which has been inade-
quately assessed begins to be incorporated into routine
practice.
Methods and design
Trial Eligibility
Hospitals will be eligible for entry if they can provide neo-
natal intensive or special care, can achieve satisfactory
rates of follow up at two years and would be able to insti-
tute the routine use of adjuvant IVIG for babies with sepsis
if the trial demonstrates evidence of benefit.
Babies are eligible if:
1. They are receiving antibiotics and have proven or sus-
pected serious infection
AND
2. They have at least one of following:
• birthweight less than 1500 g OR
• evidence of infection in blood culture, CSF or usually
sterile body fluid OR
• respiratory support via an endotracheal tube
AND
3. There is substantial uncertainty that IVIG is indicated
Exclusion criteria are:
1. IVIG has already been given
2. IVIG is thought to be needed or contra-indicated (e.g.
because of severe congenital abnormality or contra-indi-
cations in the manufacturer's licensed product informa-
tion sheet)
Recruitment and Trial Entry
Recruitment will depend on good teamwork, knowledge
and confidence among all clinicians, particularly front
line nursing and medical staff, so that parents receive
appropriate information about the study before entry and
throughout their baby's stay. The ORACLE study recruited
over 11,000 infants in 161 centres [53,54]. Experience
from that trial suggests that it is helpful if nurses and doc-
tors understand the study background, see clinical
research as an integral part of neonatal care contributing
to future quality of care, and if a named nurse is appointed
and trained as a local Trial Co-ordinator. If those caring
for the baby are well informed about the study, they can
discuss it without transmitting anxiety. Indeed, parents
are likely to feel less anxious if given the opportunity to
discuss the options for their baby's treatment in the con-
text of the study with knowledgeable staff.
The named nursing and medical representative in each
unit will therefore receive opportunities for training, regu-
lar information and support to enable them to orientate
and update new and established nursing and medical
staff. The protocol, printed materials and relevant new
research will be widely available and staff will be kept
informed by newsletters, personal visits and the study
website http://www.npeu.ox.ac.uk/INIS.
Many babies receive antibiotics for sepsis during their stay
in a neonatal unit. Some babies may be given antibiotics
more for prophylaxis than for treatment of suspected sep-
sis. The threshold for considering entry into INIS must be
that there is a clinical suspicion that this baby has sepsis.
Once an infant is considered eligible, it is important that
enrolment takes place as soon as practically possible.
All parents should routinely be given an information leaf-
let about INIS by the nursing staff when their baby is
admitted to the neonatal unit. This will include details of
their local medical and nursing contact with whom they
can discuss the study [55]. If their baby becomes eligible
they will be asked for consent to participate in the study,
and later follow up, by the most appropriate member of
staff available, in person or by telephone. If they consent
in person a copy of the signed consent form will be given
to the parent(s). If telephone consent is considered neces-
sary and appropriate by the recruiting clinician, a 'Tele-
phone Consent' form will be completed. This form
should then be read and signed by the parent(s) at their
next visit to the hospital. Once this has happened, a copy
of the consent form will be given to the parent(s).
Treatment Allocation
The practical arrangements for random allocation to trial
groups will be as simple as possible, based on that used in
the ORACLE study [53,54]. Staff will open the next
sequentially numbered study pack kept in the neonatal
unit, which contains all the materials necessary to give a
course of study drug.
Clinical Management
IVIG group
an intravenous infusion of IVIG of 10 ml per kg, repeated
after 48 hours.
Control group
an intravenous infusion of 10 ml per kg of 0.2% albumin
solution (placebo) repeated after 48 hours.Page 6 of 13
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ourless and froth on agitation [see Additional File 1].
Administration of treatment
The IVIG or placebo infusion will be given according to
the manufacturer's instructions, over about 4–6 hours. A
second, similar, dose will be given at or around 48 hours
after the first dose. No further IVIG or placebo should be
given, in this or any subsequent episodes of sepsis.
Neonatal management
All other aspects of neonatal management will be left to
the discretion of the paediatrician responsible for care. No
special investigations and no delays of discharge will be
required.
Measurement of Outcome
Primary outcome measure
1. Mortality or major disability at two years, corrected for
gestational age
Secondary short term outcomes
2. Mortality, chronic lung disease or major cerebral abnor-
mality before hospital discharge, significant positive cul-
ture after trial entry, pneumonia, necrotising enterocolitis,
duration of respiratory support
Secondary long term outcomes
3. Mortality before two years, major disability at 2 years,
non-major disability at 2 years
Health service utilisation
4. Length of hospital stay and number of hospital admis-
sions
Data Collection
Hospital mortality, chronic lung disease, major cerebral
abnormality and length of stay will be assessed from case
notes. Major disability at two years will be assessed by
questionnaires sent to the child's parents and health care
professionals. Major disability will be defined according
to the criteria set out in the National Perinatal Epidemiol-
ogy Unit (NPEU) and Oxford Regional Health Authority
document and will include any major disability in the fol-
lowing domains: neuromotor function, seizures, auditory
function, communication, visual function, cognitive func-
tion and other physical disability [56,57].
The parental questionnaire incorporates the parent report
component of the Parent Report of Children's Abilities
(PARCA), which was used in the 2 year follow up of the
MRC funded UKOS trial [58]. This shortened version of
the PARCA was acceptable to parents, with a high
response rate in UKOS, and is currently being validated by
the UKOS team. The PARCA score (both parent report and
parent administered components) has been validated and
was found to predict performance on the Mental Develop-
ment Index of the Bayley Scales of Infant Development II
[58,59]. The overall score for the modified PARCA will
give a measure of verbal and non-verbal cognitive abili-
ties. The parents' questionnaire also includes questions
about temperament, which may give an early indication
of behavioural and attentional difficulties, and also
includes questions about respiratory function, hearing,
vision, hospital admissions, relevant diagnoses and cur-
rent function in a number of domains, allowing categori-
sation of disability as major or non-major.
Experience of other trials in this area at the NPEU, Oxford
and elsewhere, suggests that it is possible to determine
early neonatal events for all babies recruited. Loss to fol-
low-up after hospital discharge of the child is more prob-
lematic.
There are likely to be few children who cannot be traced
in the UK either through the hospital of recruitment or the
NHS Central Register. Similar high rates of follow-up will
be expected in countries participating outside the UK.
Analysis
An intention to treat analysis will be performed compar-
ing the outcome of all children allocated IVIG with all
those allocated placebo, regardless of what treatment was
received, or how complete that treatment was. Statistical
analysis will calculate the relative risk of an outcome in
the IVIG group compared with the placebo group along
with a 95% confidence interval. For subgroup analyses,
99% confidence intervals will be calculated to take
account of the number of comparisons.
Subgroup analyses
Ten subgroup analyses will also be undertaken, stratifying
by the factors described below.
1. Birth weight. Infants of very low birth weight (VLBW: <
1500 g) v infants with birth weight ≥ 1500 g
2. Small for gestational age infants (< 10th centile) v
infants ≥ 10th centile
3. Gestational age at birth: < 26 weeks, 26+0 to 27+6
weeks, 28+0 to 29+6 weeks, 30+0 weeks or more
4. Gender: male vs female
5. Maternal chorioamnionitis: infants born at < 30 weeks
gestation to women with clinical chorioamnionitis v
infants born at < 30 weeks gestation with no clinical cho-
rioamnionitis v infants born at ≥ 30 weeksPage 7 of 13
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tation to women with elevated CRP (> 80 mg/l) v infants
born at < 30 weeks gestation with no elevated maternal
CRP v infants born at ≥ 30 weeks
7. Preterm birth and duration of membrane rupture: Born
at < 37 weeks and membranes ruptured for < 24 hours,
24–48 hours or > 48 hours versus born at ≥ 37 weeks
8. Clinical markers of mortality risk:
(i) Clinical evidence of high mortality risk: looking
seriously ill or inactive, and has:
(a) capillary refill time > 3 seconds OR
(b) bowel perforation or definite necrotising ente-
rocolitis OR
(c) prolonged bleeding from puncture sites OR
(d) ventilated, SaO2/FiO2 ratio or PaO2/FiO2 ratio
consistent with > 15% mortality risk for gestation
OR
(e) pH consistent with > 15% mortality risk for
gestation. [SaO2/FiO2 ratio, PaO2/FiO2 ratio and
pH consistent with > 15% mortality risk will be
extrapolated from oxygenation and pH data in a
prospective cohort of 14,000 infants (UK Neonatal
Staffing Study) by methods similar to that used in
the development of the MRC funded CRIB score
[6]]
(ii) Intermediate mortality risk: not satisfying criteria
for high risk, but has:
(a) Total white cell count < 5 × 109/l OR
(b) CRP above 15 mg/l OR
(c) platelet count < 50 × 109/l OR
(d) organism(s) isolated in blood or usually sterile
site OR
(e) pneumonia on chest X-ray OR
(f) CSF consistent with bacterial meningitis
(iii) Other: not satisfying criteria for high or interme-
diate risk
9. Type of infection:
(i) Early onset infection (non-contaminant organisms
isolated from culture sent before 48 hours):
(a) group B streptococcal disease
(b) other pathogens
(c) indeterminate aetiology
(ii) Late onset infection (non-contaminant organism
isolated from culture sent after 48 hours):
(a) gram positive organisms except coagulase nega-
tive staphylococcus
(b) coagulase negative staphylococcus
(c) gram negative organisms
(d) fungal infection
(e) other pathogens
(f) indeterminate aetiology
(iii) Post surgery
10. Type of IVIG. This subgroup analysis will analyse sep-
arately babies recruited in hospitals using the different
IVIG products included in INIS. This subgroup analysis
will include baseline characteristics and treatments after
randomisation as well as outcomes.
Interim analyses: the Data Monitoring and Ethics 
Committee
For the trial, a Data Monitoring and Ethics Committee
(DMEC) has been established. This is independent of the
trial organisers and meets at least once per year. During
the period of recruitment to the trial, interim analyses are
supplied, in strict confidence, to the DMEC, together with
any other analyses the DMEC may request. In the light of
interim data, and other evidence from relevant studies
(including updated overviews of the relevant randomised
controlled trials), the DMEC will inform the Trial Steering
Committee, if in their view: i) there is proof beyond rea-
sonable doubt that the data indicate that any part of the
protocol under investigation is either clearly indicated or
contra-indicated, either for all infants or for a particular
subgroup of trial participants, or ii) it is evident that no
clear outcome will be obtained. Decision to inform the
Trial Steering Committee in either of these circumstances
will in part be based on statistical considerations.
Appropriate criteria for proof beyond reasonable doubt
cannot be specified precisely. A difference of at least 3Page 8 of 13
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point may be needed to justify halting, or modifying, such
a study prematurely. If this criterion were to be adopted, it
would have the practical advantage that the exact number
of interim analyses would be of little importance, and so
no fixed schedule is proposed [60].
Unless modification or cessation of the protocol is recom-
mended by the DMEC, the Trial Steering Committee, col-
laborators and administrative staff (except those who
supply the confidential information) will remain ignorant
of the results of the interim analysis. Collaborators and all
others associated with the study may write through the
trial office to the DMEC to draw attention to any concern
they may have about the possibility of harm arising from
the treatment under study, or about any other matters that
may be relevant.
The membership of the Data Monitoring and Ethics Com-
mittee is :
Professor Adrian Grant (Chair)
Professor Forrester Cockburn
Professor Deborah Ashby
Mrs Hazel Thornton
Professor Neena Modi
Dr Brian McClelland
Sample Size and Feasibility
Table 4 shows positive blood culture rates (including
probable contaminants) in 3,963 consecutive infants of
all birthweights admitted to a randomly selected, nation-
ally representative cohort of 54 UK neonatal units
between 1st March 1998 and 4th September 1998 in a
study of organisation and outcomes of neonatal care
funded by the NHS Executive [6].
Among VLBW infants with positive blood cultures, mor-
tality was 14%. In a North American cohort, mortality in
VLBW infants with septicaemia was 21% [7]. Assuming
combined rates of mortality and major morbidity of 10–
20% for all infants and 20–30% for VLBW infants, Table
5 outlines estimated sample sizes.
Feasibility
About 5,000 infants will be needed to demonstrate mod-
erate reductions in mortality or survival with major devel-
opmental delay with adequate power. Over a three year
recruitment period, assuming that 7–10% of all admis-
sions are diagnosed with clinical sepsis and considered
eligible for recruitment, 150 NICUs with an average of
300 admissions per year will be required to achieve the
recruitment target, assuming a 40–50% rate of recruit-
ment of eligible infants. Neonatal units will initially be
recruited in the UK, Australia and New Zealand. A census
of all 186 UK neonatal intensive care units (NICUs) and
60 special care baby units in 1996 (which is a 100%
response rate) found that the median number of admis-
sions per year per NICU was 317 [61]. If a broadly repre-
sentative sample of about half of all UK NICUs and
SCBUs participate, then over 50% of the projected recruit-
ment rate for the trial will be possible within the UK, leav-
ing the additional 50% to be recruited from the rest of the
world.
This study reflects the philosophy that the only practicable
way to achieve comparisons which are sufficiently large to
minimise the risk of being seriously misled by the play of
chance is to design trials that are extremely simple and
flexible [62].
Experience in the OSIRIS and ORACLE studies suggests
that a large, simple trial of this scale of a potentially
important intervention is feasible [63,53,54]. Further-
more, systematic reviews of RCTs of IVIG therapy in neo-
natal sepsis suggest a substantial reduction in mortality.
This contrasts with the systematic reviews of RCTs of anti-
biotics in threatened preterm birth which led to the ORA-
CLE study, as these showed no evidence of a difference in
neonatal mortality. This preliminary evidence that IVIG
may reduce mortality may further enhance the appeal of
the study.
The estimate of the incidence of the outcome (the event
rate) for the trial is imprecise, particularly as the threshold
at which clinicians will enter patients cannot be esti-
mated. If clinicians enter babies where the likelihood of
serious sepsis is lower then the event rate will also be
lower. If clinicians restrict entry to only those babies who
are very sick, then the event rate will be high. Either of
these two scenarios is reasonable because it will define a
population to which the trial result can be generalised.
However, it does mean that until the trial has recruited
Table 4: Positive blood culture rates
Number with positive cultures Mortality (all causes) Number with negative cultures Mortality (all causes)
204/3,963 (5%) 16/204 (8%) 3,759/3,963 (95%) 95/3,759 (2.5%)Page 9 of 13
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determine the optimum trial sample size with any cer-
tainty. As a consequence the trial sample size currently
represents the minimum size desirable. Assuming the trial
recruits for three years, the maximum number of babies
which can be recruited during this time will be recruited
and it is possible that this number may exceed 5,000. Dur-
ing recruitment to the trial the accumulating data will be
seen by an independent Data Monitoring and Ethics
Committee at least once per year (see above) and they will
advise the Trial Steering Committee whether the trial has
answered the clinical question being addressed. If not, the
trial will continue to recruit until 5,000 babies have been
recruited, or until funding is exhausted.
Publication Policy
To safeguard the scientific integrity of the trial, data from
this study should not be presented in public or submitted
for publication without requesting consent from the Trial
Steering Committee (see Organisation below). The suc-
cess of the trial depends on the collaboration of a large
number of doctors and nurses. For this reason, chief credit
for the results will be given not to the committees or cen-
tral organisers but to all who have collaborated in the
study. Acknowledgement will include all members of the
trial committees, the data co-ordinating centre, trial staff,
and local co-ordinators at all collaborating centres.
Authorship at the head of the paper will take the form;
"The INIS Study Collaborative Group". This is the pre-
ferred option, as it avoids giving undue prominence to
any individuals. All contributors to the study will be listed
at the end of the report, with their contribution to the
study identified.
Organisation
The protocol received Multi-Centre Research Ethics Com-
mittee (MREC) approval from the Anglia and Oxford
MREC on 16 October 2000 (Reference number: 00/05/
53). Each country will obtain ethics approval prior to
recruitment commencing.
Trial Steering Committee (see Table 6)
The Trial Steering Committee (TSC) provides overall
supervision of the trial on behalf of the Medical Research
Council. Its terms of reference are:
1. To monitor and supervise the progress of the trial
towards its interim and overall objectives
2. To review at regular intervals relevant information from
other sources (e.g. related trials)
3. To consider the recommendations of the Data Monitor-
ing and Ethics Committee
4. In the light of 1, 2 and 3 above, to inform the MRC
Council and relevant MRC Research Boards on the
progress of the trial
5. To advise the MRC Council on publicity and the pres-
entation of all aspects of the trial
Meetings of the TSC will take place at least once per year.
Study Investigators' Group
The Investigators' Group will consist of the trial investiga-
tors, representatives of specific groups whose expertise is
Table 5: Range of estimated sample sizes
Mortality or major 
morbidity in control 
group
Mortality or major 
morbidity in IVIG group
Relative risk reduction Total sample size required to detect difference 
with 95% confidence
80% power 90% power
30% 26% 13% 4,052 5,392
30% 25% 17% 2,580 3,428
30% 20% 33% 626 824
25% 21% 16% 3,572 4,748
25% 20% 20% 2,266 3,006
25% 15% 40% 540 708
20% 16% 20% 2,994 3,972
20% 15% 25% 1,890 2,502
20% 12.5% 37.5% 810 1,066
15% 12% 20% 4,204 5,582
15% 10% 33% 1,450 1,914
12% 9% 25% 3,408 4,516
10% 7.5% 25% 4,166 5,524Page 10 of 13
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studies. This group will supervise the practical aspects of
the trial's conduct. It will resolve problems brought to it
by the Project Management Group (see below) and will be
responsible for organising reporting and dissemination of
the trial's results.
Project Management Group
The Project Management Group will oversee the day-to-
day running of the trial.
The responsibilities of the Project Management Group
include:
i) Recruitment of participating centres
ii) Distribution and supply of data collection forms and
other appropriate documentation for the trial
iii) Data collection and management
iv) Organisation of the distribution system for the treat-
ment packs
v) Organisation of the follow-up of children at 2 years of
age, including the distribution of questionnaires, follow-
up of non-responders and liaison with local 'follow-up'
personnel
vi) Data entry and cleaning
vii) Data analysis
viii) Collection of adverse event data
ix) Organising and servicing the Data Monitoring and Eth-
ics Committee
Local Co-ordination
Each participating centre will identify a local medical co-
ordinator and a local neonatal nurse co-ordinator (as nec-
essary). The responsibility of the local co-ordinators will
be to:
i) Be familiar with the trial
ii) Liaise with the INIS Co-ordinating Centre
iii) Ensure that all staff involved in the care of babies on
the neonatal unit are informed about the trial
iv) Ensure that mechanisms for recruitment of eligible
babies (including information material) are in place,
monitor their effectiveness, and discuss reasons for the
non-recruitment of any eligible babies with relevant staff
v) Ensure that supplies of data collection forms are always
available, that they are completed and returned to the
INIS Co-ordinating Centre promptly, and to deal with any
queries arising
vi) Notify the INIS Co-ordinating Centre of any serious
adverse events
vii) Facilitate other aspects of local collaboration as
appropriate
viii) Make all data available for verification, audit and
inspection purposes as necessary
ix) Ensure that the confidentiality of all information
about trial participants is respected by all persons
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